NICE publishes draft guidance on ovarian cancer drug
Draft guidance on the use of bevacizumab as a treatment for women with advanced ovarian cancer has been published by the National Institute for Health and Clinical Excellence (NICE).
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
- Customised email alerts straight to your inbox (30+ alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units